logo-loader
viewNyrada

Nyrada Inc developing exciting drugs for cholesterol and 'first-ever treatment' for brain injury

Nyrada Inc's (ASX:NYR) James Bonnar tells Proactive's Andrew Scott they listed on the ASX in January this year and are working on two really exciting drugs - the first is what he believes to be the first-ever treatment for brain injury and the second is a cholesterol-lowering drug. He says what makes their brain injury candidate unique and sets it apart from what is available currently is that it's a small molecule drug which means it's cheap to produce and can be formulated in a pill. Bonnar says its cholesterol lowering drug will get into the clinic late next year and will be shortly followed by their brain injury drug. He says they're both addressing very large markets - each in the area of US$20bn

Quick facts: Nyrada

Price: 0.22 AUD

ASX:NYR
Market: ASX
Market Cap: $24.06 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

ImmuPharma’s partner Avion set to meet FDA in December to discuss Phase 3...

Dr Tim Franklin, Chief Operating Officer of ImmuPharma PLC (LON:IMM) joins Proactive London's Katie Pilbeam to discuss ImmuPharma's announcement that The US Food & Drug Administration (“FDA”) has confirmed 4th December 2020 will be the date for the Type ‘A’ Meeting Request, with Avion...

49 minutes ago

2 min read